WinningMatrix brings together biomarker evidence, companion diagnostics, targeted therapies, clinical trials, regulatory labels, real world evidence and market access signals in one structured intelligence dashboard.
For biopharma, diagnostics, hospitals, investors and access teams, precision medicine analysis now requires a connected view of biomarker validation, assay readiness, therapy labels, clinical trial criteria, treatment pathways and reimbursement conditions.
The Precision Medicine Intelligence Dashboard is designed as a decision support layer for teams that need to understand which biomarkers are clinically actionable, which tests support patient selection, which therapies depend on diagnostic evidence and where adoption barriers may affect commercial performance.
Each module is designed to help clients answer clinical, commercial, regulatory, access and partnering questions across the precision medicine value chain.
Track actionable biomarkers and variants across DNA, RNA, protein, expression, immune, pathology and liquid biopsy evidence categories.
Connect test names, diagnostic developers, sample types, technology platforms, intended use and therapy selection requirements.
Map targeted therapies to biomarker selected populations, indications, line of therapy, label language and patient selection logic.
Analyze biomarker stratified trials across protocol design, inclusion criteria, endpoints, sponsor, geography, status and readout signals.
Track approvals, label updates, CDx co-approval events, test claims, agency actions and relevant guideline movements by geography.
Understand test utilization, treatment sequencing, response patterns, adherence, safety, outcomes and care pathway variation.
Profile therapy sponsors, diagnostic developers, sequencing platforms, AI pathology companies, liquid biopsy players and co-development partnerships.
Assess payer policy, coding pathways, price signals, coverage decisions, reimbursement conditions and test adoption bottlenecks.
The dashboard helps clients move from fragmented precision medicine data points to a consolidated view of biomarker opportunity, diagnostic readiness and therapy adoption risk.
Compare biomarkers by disease area, alteration type, evidence maturity, test availability and therapy relevance.
Map companion diagnostics and assays to sample type, platform, regulatory status, intended use and therapy linkage.
Evaluate target biology, label language, indication scope, line of therapy and biomarker based positioning.
Analyze biomarker stratified clinical trials, inclusion criteria, endpoints, trial geography and readout momentum.
Identify coverage gaps, reimbursement barriers, test access issues, care pathway friction and payer evidence needs.
Screen diagnostic developers, therapy sponsors, platform companies and co-development partnerships across the ecosystem.
The dashboard supports biomarker strategy, diagnostic development, clinical trial planning, commercial access, investment screening and competitive monitoring.
Track assay positioning, CDx pathways, biomarker validation and therapy linked demand signals.
Benchmark biomarker strategies, competitive differentiation and patient selection opportunities.
Evaluate inclusion criteria, endpoint choices, trial geography and biomarker based trial design.
Understand testing workflows, treatment pathway gaps and diagnostic access barriers.
Assess reimbursement barriers, payer evidence needs, coding pathways and access constraints.
Screen biomarkers, CDx partnerships, platforms, therapy sponsors and acquisition targets.
Access is tailored around your team’s priorities, from biomarker mapping and CDx tracking to clinical development, market access and partnership screening.
Share your business use case, disease area focus, biomarker priorities and preferred output format.
Select the modules, geographies, disease areas, biomarker classes and company coverage required.
Access structured precision medicine intelligence with source notes, definitions and decision ready views.
Extend the dashboard with new disease areas, deeper diagnostic mapping, payer coverage or periodic updates.
Explore how the dashboard supports biomarker strategy, companion diagnostic planning, targeted therapy analysis and market access decisions.
It covers biomarker intelligence, companion diagnostics, targeted therapies, clinical trial design, regulatory labels, real world evidence, company profiles and market access intelligence.
Yes. The dashboard links biomarkers, assays, sample types, platform technologies, diagnostic developers, regulatory status and therapy selection requirements.
Yes. The structure supports oncology and other biomarker led disease areas where therapy selection and trial eligibility depend on molecular or diagnostic evidence.
Yes. Teams can assess biomarker inclusion criteria, trial stratification, comparator strategy, endpoints, patient selection logic and readout signals.
Market access teams can evaluate test coverage, reimbursement barriers, coding pathways, payer evidence needs and adoption bottlenecks.
Yes. Coverage can be tailored by disease area, biomarker class, therapy category, diagnostic platform, geography, company set and strategic use case.
Request access to the WinningMatrix Precision Medicine Intelligence Dashboard and get a structured view of biomarkers, companion diagnostics, targeted therapies, trials, regulatory labels, evidence and market access signals.
Built for professional market intelligence workflows